{"id":87650,"date":"2018-07-30T19:26:05","date_gmt":"2018-07-30T16:26:05","guid":{"rendered":"https:\/\/newsroom.su\/?p=87650"},"modified":"2018-07-30T19:26:05","modified_gmt":"2018-07-30T16:26:05","slug":"pharmamar-reaches-an-agreement-with-impilo-pharma-a-part-of-immedica-group-for-the-promotion-and-distribution-of-yondelisr-in-the-nordic-countries-and-eastern-europe","status":"publish","type":"post","link":"https:\/\/newsroom.su\/?p=87650","title":{"rendered":"PharmaMar Reaches an Agreement With Impilo Pharma, a Part of Immedica Group, for the Promotion and Distribution of Yondelis(R) in the Nordic Countries and Eastern Europe"},"content":{"rendered":"<div class=\"8a53641db43077f6712193da0bbeb89a\" data-index=\"1\" style=\"float: none; margin:10px 0 10px 0; text-align:center;\">\n<script async src=\"\/\/pagead2.googlesyndication.com\/pagead\/js\/adsbygoogle.js\"><\/script>\r\n<!-- 1 newsroom -->\r\n<ins class=\"adsbygoogle\"\r\n     style=\"display:inline-block;width:468px;height:60px\"\r\n     data-ad-client=\"ca-pub-2753775886465733\"\r\n     data-ad-slot=\"8795226203\"><\/ins>\r\n<script>\r\n(adsbygoogle = window.adsbygoogle || []).push({});\r\n<\/script>\r\n<div id=\"mpuls-widget-471\"><\/div>\r\n<script language=\"javascript\" type=\"text\/javascript\">\r\n(function() {\r\nvar useSSL = 'https:' == document.location.protocol;\r\nvar mpuls = document.createElement('script');\r\nmpuls.type = 'text\/javascript'; mpuls.async = true;mpuls.charset = 'UTF-8';\r\nmpuls.src = (useSSL ? 'https:' : 'http:') + '\/\/www.mpuls.ru\/load\/471.js';\r\nvar nrvrscr = document.getElementsByTagName('script')[0];\r\nnrvrscr.parentNode.insertBefore(mpuls, nrvrscr);\r\n})();\r\n<\/script>\n<\/div>\n<p><a href=\"https:\/\/newsroom.su\/wp-content\/uploads\/2018\/07\/11.jpg\"><img loading=\"lazy\" decoding=\"async\" class=\"alignleft size-medium wp-image-87652\" src=\"https:\/\/newsroom.su\/wp-content\/uploads\/2018\/07\/11-300x197.jpg\" alt=\"\" width=\"300\" height=\"197\" srcset=\"https:\/\/newsroom.su\/wp-content\/uploads\/2018\/07\/11-300x197.jpg 300w, https:\/\/newsroom.su\/wp-content\/uploads\/2018\/07\/11-768x503.jpg 768w, https:\/\/newsroom.su\/wp-content\/uploads\/2018\/07\/11.jpg 900w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/><\/a>MADRID, July 27, 2018\/PRNewswire-FirstCall\/ &#8212;<\/p>\n<pre>\t    \r\n    - PharmaMar will receive an up-front payment of 2 million euros\r\n    - This agreement\u00a0will replace\u00a0the\u00a0current\u00a0agreement\u00a0between\u00a0PharmaMar\u00a0and\u00a0Swedish\r\n      Orphan\u00a0Biovitrum\u00a0International\r\n\r\n<\/pre>\n<p>PharmaMar (MCE: PHM) has announced today the signing of an agreement with Impilo<br \/>\nPharma, a part of Immedica Group, for the exclusive promotion and distribution of its<br \/>\nantitumour compound, Yondelis(R), throughout the Nordic countries and Eastern Europe. This<br \/>\nagreement will come into effect in six months.<\/p>\n<p>(Logo: http:\/\/mma.prnewswire.com\/media\/624563\/PharmaMar_Logo.jpg )<\/p>\n<p>According to the terms of the agreement, PharmaMar will receive an up-front payment of<br \/>\n2 million euros. Impilo Pharma will be responsible for the promotion and the distribution<br \/>\nof Yondelis(R)\u00a0throughout the above mentioned territories, and PharmaMar will be the<br \/>\nmanufacturer of the product.<\/p>\n<p>This agreement will replace the current contract between PharmaMar and Swedish Orphan<br \/>\nBiovitrum International for the promotion and distribution of Yondelis(R)\u00a0in the Nordic<br \/>\ncountries and Eastern Europe.<\/p>\n<p>&#171;This agreement will help us to strengthen the sales of Yondelis(R)\u00a0even more<br \/>\nthroughout various European Countries,\u00a0also maintaining our\u00a0compromise\u00a0with the patients,<br \/>\nfacilitating\u00a0their access to novel\u00a0therapies,&#187;\u00a0explains\u00a0Luis Mora, Managing Director of<br \/>\nthe Oncology Business Unit at PharmaMar.<\/p>\n<p>About PharmaMar<\/p>\n<p>Headquartered in Madrid, PharmaMar is a world-leading biopharmaceutical company in the<br \/>\ndiscovery and development of innovative marine-derived anticancer drugs. The company has a<br \/>\npipeline of drug candidates and a robust R&amp;D oncology program. PharmaMar develops and<br \/>\ncommercializes YONDELIS(R)\u00a0in Europe and has other clinical-stage programs under<br \/>\ndevelopment for several types of solid and hematological cancers, Zepsyre(R)<br \/>\n(lurbinectedin, PM1183), PM184 and PM14. PharmaMar is a global biopharmaceutical company<br \/>\nwith subsidiaries in Germany, Italy, France, Switzerland, United Kingdom, Belgium, Austria<br \/>\nand the United States. PharmaMar fully owns other companies: GENOMICA, a leading molecular<br \/>\ndiagnostics company; Sylentis, dedicated to researching therapeutic applications of gene<br \/>\nsilencing (RNAi); and two other chemical enterprises, Zelnova Zeltia and Xylazel. To learn<br \/>\nmore about PharmaMar, please visit us at\u00a0http:\/\/www.pharmamar.com.<\/p>\n<p>About YONDELIS(R)\u00a0(trabectedin)<\/p>\n<p>YONDELIS(R)\u00a0(trabectedin) is a multimodal, synthetically produced antitumor agent,<br \/>\noriginally derived from the sea squirt,\u00a0Ecteinascidia turbinata. The drug exerts its<br \/>\nactivity by targeting the transcriptional machinery and impairing DNA repair. It is<br \/>\napproved in close 80 countries in North America, Europe, South America and Asia for the<br \/>\ntreatment of advanced soft tissue sarcomas as a single-agent and for relapsed ovarian<br \/>\ncancer in combination with DOXIL(R)\/CAELYX(R) (doxorubicin HCl liposome injection) in the<br \/>\nEuropean Union. Under a licensing agreement with PharmaMar, Janssen Products, L.P. has the<br \/>\nrights to develop and sell YONDELIS(R)\u00a0globally except in Europe, where PharmaMar holds<br \/>\nthe rights, and in Japan, where PharmaMar has granted a license to Taiho Pharmaceuticals.<\/p>\n<p>About Immedica AB<\/p>\n<p>Immedica is a fast growing private European niche pharma company. The company is based<br \/>\nin Stockholm, Sweden, and has a pan-European commercial coverage with the Nordics as its<br \/>\nstronghold.<\/p>\n<p>Immedica provides significant know-how and experience from commercialization of<br \/>\nniche\/specialty care products across the European and Middle East territories, and the<br \/>\ncompany&#8217;s management team has an outstanding track record of operating niche pharma<br \/>\nproducts in Europe. Immedica has capabilities to provide optimal access of specialty care<br \/>\nmedicines to patients with significant medical needs, including key areas such as<br \/>\nregulatory affairs, pharmacovigilance, medical affairs, pricing &amp; reimbursement, and<br \/>\nproduct distribution.<\/p>\n<p>Today, Immedica manage many of its products via operations at Medical Need Europe, a<br \/>\nniche\/orphan pharma company recently acquired. Immedica&#8217;s main owner is Impilo AB, a<br \/>\nprivate Swedish Health Care investment company established in 2017, and with more than SEK<br \/>\n3.5 bn in capital from leading Nordic and international investors. More information is<br \/>\navailable at\u00a0www.immedica.com or www.medicalneed.com<\/p>\n<p>Disclaimer<\/p>\n<p>This document is a press release, not a prospectus. This document does not constitute<br \/>\nor form part of an offering or invitation to sell or a solicitation to purchase, offer or<br \/>\nsubscribe shares of the company. Moreover, no reliance should be placed upon this document<br \/>\nfor any investment decision or contract and it does not constitute a recommendation of any<br \/>\ntype with regard to the shares of the company.<\/p>\n<p><a class=\"twitter-timeline\" data-width=\"640\" data-height=\"960\" data-dnt=\"true\" href=\"https:\/\/twitter.com\/PhrmMar?ref_src=twsrc%5Etfw\">Tweets by PhrmMar<\/a><script async src=\"https:\/\/platform.twitter.com\/widgets.js\" charset=\"utf-8\"><\/script><\/p>\n<p>https:\/\/es-la.facebook.com\/PharmaMarES<\/p>\n<p>https:\/\/www.linkedin.com\/company\/pharmamar<\/p>\n<p>https:\/\/www.instagram.com\/pharmamar<\/p>\n<p>https:\/\/www.youtube.com\/c\/Pharmamar_official<\/p>\n<p>Media Contact:<\/p>\n<p>Alfonso Ortin, Communications Director,\u00a0aortin@pharmamar.com,\u00a0Mobile:<br \/>\n+34-609493127<br \/>\nMiguel Martinez-Cava, Digital Communication Manager,\u00a0mmartinez-cava@pharmamar.com,<br \/>\nMobile: +34-606597464<br \/>\nPhone: +34-918466000<\/p>\n<p>Investor Relations:<\/p>\n<p>Phone: +34-914444500<br \/>\nOr please visit our website at\u00a0http:\/\/www.pharmamar.com<\/p>\n<p>Photo:<br \/>\nhttp:\/\/mma.prnewswire.com\/media\/624563\/PharmaMar_Logo.jpg<\/p>\n<p>Source:<br \/>\nPharmaMar<\/p>\n<div class=\"8a53641db43077f6712193da0bbeb89a\" data-index=\"1\" style=\"float: none; margin:10px 0 10px 0; text-align:center;\">\n<script async src=\"\/\/pagead2.googlesyndication.com\/pagead\/js\/adsbygoogle.js\"><\/script>\r\n<!-- 1 newsroom -->\r\n<ins class=\"adsbygoogle\"\r\n     style=\"display:inline-block;width:468px;height:60px\"\r\n     data-ad-client=\"ca-pub-2753775886465733\"\r\n     data-ad-slot=\"8795226203\"><\/ins>\r\n<script>\r\n(adsbygoogle = window.adsbygoogle || []).push({});\r\n<\/script>\r\n<div id=\"mpuls-widget-471\"><\/div>\r\n<script language=\"javascript\" type=\"text\/javascript\">\r\n(function() {\r\nvar useSSL = 'https:' == document.location.protocol;\r\nvar mpuls = document.createElement('script');\r\nmpuls.type = 'text\/javascript'; mpuls.async = true;mpuls.charset = 'UTF-8';\r\nmpuls.src = (useSSL ? 'https:' : 'http:') + '\/\/www.mpuls.ru\/load\/471.js';\r\nvar nrvrscr = document.getElementsByTagName('script')[0];\r\nnrvrscr.parentNode.insertBefore(mpuls, nrvrscr);\r\n})();\r\n<\/script>\n<\/div>\n\n<div style=\"font-size: 0px; height: 0px; line-height: 0px; margin: 0; padding: 0; clear: both;\"><\/div>","protected":false},"excerpt":{"rendered":"<p>MADRID, July 27, 2018\/PRNewswire-FirstCall\/ &#8212; &#8212; PharmaMar will receive an up-front payment of 2 million euros &#8212; This agreement\u00a0will replace\u00a0the\u00a0current\u00a0agreement\u00a0between\u00a0PharmaMar\u00a0and\u00a0Swedish Orphan\u00a0Biovitrum\u00a0International PharmaMar (MCE: PHM) has announced today the signing of an agreement with Impilo Pharma, a part of Immedica Group, for the exclusive promotion and distribution of its antitumour compound, Yondelis(R), throughout the Nordic countries&#8230;<\/p>\n","protected":false},"author":10,"featured_media":87652,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","tstyn_error":""},"categories":[3],"tags":[129],"class_list":["post-87650","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-na-e-krane","tag-meditsina"],"aioseo_notices":[],"aioseo_head":"\n\t\t<!-- All in One SEO 4.9.8 - aioseo.com -->\n\t<meta name=\"description\" content=\"MADRID, July 27, 2018\/PRNewswire-FirstCall\/ -- - PharmaMar will receive an up-front payment of 2 million euros - This agreement will replace the current agreement between PharmaMar and Swedish Orphan Biovitrum International PharmaMar (MCE: PHM) has announced today the signing of an agreement with Impilo Pharma, a part of Immedica Group, for the exclusive promotion and distribution of its antitumour compound, Yondelis(R), throughout the Nordic countries\" \/>\n\t<meta name=\"robots\" content=\"max-image-preview:large\" \/>\n\t<meta name=\"author\" content=\"\u042f\u043a\u043e\u0432 \u0411\u043e\u0439\u043a\u043e\u0432\"\/>\n\t<link rel=\"canonical\" href=\"https:\/\/newsroom.su\/?p=87650\" \/>\n\t<meta name=\"generator\" content=\"All in One SEO (AIOSEO) 4.9.8\" \/>\n\t\t<meta property=\"og:locale\" content=\"ru_RU\" \/>\n\t\t<meta property=\"og:site_name\" content=\"newsroom.su - \u041d\u043e\u0432\u043e\u0441\u0442\u0438 \u043e \u043d\u043e\u0432\u043e\u0441\u0442\u044f\u0445\" \/>\n\t\t<meta property=\"og:type\" content=\"article\" \/>\n\t\t<meta property=\"og:title\" content=\"PharmaMar Reaches an Agreement With Impilo Pharma, a Part of Immedica Group, for the Promotion and Distribution of Yondelis(R) in the Nordic Countries and Eastern Europe - newsroom.su\" \/>\n\t\t<meta property=\"og:description\" content=\"MADRID, July 27, 2018\/PRNewswire-FirstCall\/ -- - PharmaMar will receive an up-front payment of 2 million euros - This agreement will replace the current agreement between PharmaMar and Swedish Orphan Biovitrum International PharmaMar (MCE: PHM) has announced today the signing of an agreement with Impilo Pharma, a part of Immedica Group, for the exclusive promotion and distribution of its antitumour compound, Yondelis(R), throughout the Nordic countries\" \/>\n\t\t<meta property=\"og:url\" content=\"https:\/\/newsroom.su\/?p=87650\" \/>\n\t\t<meta property=\"og:image\" content=\"https:\/\/newsroom.su\/wp-content\/uploads\/2017\/03\/logo4-2.png\" \/>\n\t\t<meta property=\"og:image:secure_url\" content=\"https:\/\/newsroom.su\/wp-content\/uploads\/2017\/03\/logo4-2.png\" \/>\n\t\t<meta property=\"og:image:width\" content=\"288\" \/>\n\t\t<meta property=\"og:image:height\" content=\"90\" \/>\n\t\t<meta property=\"article:published_time\" content=\"2018-07-30T16:26:05+00:00\" \/>\n\t\t<meta property=\"article:modified_time\" content=\"2018-07-30T16:26:05+00:00\" \/>\n\t\t<meta name=\"twitter:card\" content=\"summary\" \/>\n\t\t<meta name=\"twitter:title\" content=\"PharmaMar Reaches an Agreement With Impilo Pharma, a Part of Immedica Group, for the Promotion and Distribution of Yondelis(R) in the Nordic Countries and Eastern Europe - newsroom.su\" \/>\n\t\t<meta name=\"twitter:description\" content=\"MADRID, July 27, 2018\/PRNewswire-FirstCall\/ -- - PharmaMar will receive an up-front payment of 2 million euros - This agreement will replace the current agreement between PharmaMar and Swedish Orphan Biovitrum International PharmaMar (MCE: PHM) has announced today the signing of an agreement with Impilo Pharma, a part of Immedica Group, for the exclusive promotion and distribution of its antitumour compound, Yondelis(R), throughout the Nordic countries\" \/>\n\t\t<meta name=\"twitter:image\" content=\"https:\/\/newsroom.su\/wp-content\/uploads\/2017\/03\/logo4-2.png\" \/>\n\t\t<script type=\"application\/ld+json\" class=\"aioseo-schema\">\n\t\t\t{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"BlogPosting\",\"@id\":\"https:\\\/\\\/newsroom.su\\\/?p=87650#blogposting\",\"name\":\"PharmaMar Reaches an Agreement With Impilo Pharma, a Part of Immedica Group, for the Promotion and Distribution of Yondelis(R) in the Nordic Countries and Eastern Europe - newsroom.su\",\"headline\":\"PharmaMar Reaches an Agreement With Impilo Pharma, a Part of Immedica Group, for the Promotion and Distribution of Yondelis(R) in the Nordic Countries and Eastern Europe\",\"author\":{\"@id\":\"https:\\\/\\\/newsroom.su\\\/?author=10#author\"},\"publisher\":{\"@id\":\"https:\\\/\\\/newsroom.su\\\/#organization\"},\"image\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/newsroom.su\\\/wp-content\\\/uploads\\\/2018\\\/07\\\/11.jpg\",\"width\":900,\"height\":590},\"datePublished\":\"2018-07-30T19:26:05+03:00\",\"dateModified\":\"2018-07-30T19:26:05+03:00\",\"inLanguage\":\"ru-RU\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/newsroom.su\\\/?p=87650#webpage\"},\"isPartOf\":{\"@id\":\"https:\\\/\\\/newsroom.su\\\/?p=87650#webpage\"},\"articleSection\":\"\\u041d\\u0430 \\u044d\\u043a\\u0440\\u0430\\u043d\\u0435, \\u043c\\u0435\\u0434\\u0438\\u0446\\u0438\\u043d\\u0430\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/newsroom.su\\\/?p=87650#breadcrumblist\",\"itemListElement\":[{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/newsroom.su#listItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/newsroom.su\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/newsroom.su\\\/?cat=3#listItem\",\"name\":\"\\u041d\\u0430 \\u044d\\u043a\\u0440\\u0430\\u043d\\u0435\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/newsroom.su\\\/?cat=3#listItem\",\"position\":2,\"name\":\"\\u041d\\u0430 \\u044d\\u043a\\u0440\\u0430\\u043d\\u0435\",\"item\":\"https:\\\/\\\/newsroom.su\\\/?cat=3\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/newsroom.su\\\/?p=87650#listItem\",\"name\":\"PharmaMar Reaches an Agreement With Impilo Pharma, a Part of Immedica Group, for the Promotion and Distribution of Yondelis(R) in the Nordic Countries and Eastern Europe\"},\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/newsroom.su#listItem\",\"name\":\"Home\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/newsroom.su\\\/?p=87650#listItem\",\"position\":3,\"name\":\"PharmaMar Reaches an Agreement With Impilo Pharma, a Part of Immedica Group, for the Promotion and Distribution of Yondelis(R) in the Nordic Countries and Eastern Europe\",\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/newsroom.su\\\/?cat=3#listItem\",\"name\":\"\\u041d\\u0430 \\u044d\\u043a\\u0440\\u0430\\u043d\\u0435\"}}]},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/newsroom.su\\\/#organization\",\"name\":\"newsroom.su\",\"description\":\"\\u041d\\u043e\\u0432\\u043e\\u0441\\u0442\\u0438 \\u043e \\u043d\\u043e\\u0432\\u043e\\u0441\\u0442\\u044f\\u0445\",\"url\":\"https:\\\/\\\/newsroom.su\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/newsroom.su\\\/wp-content\\\/uploads\\\/2017\\\/03\\\/logo4-2.png\",\"@id\":\"https:\\\/\\\/newsroom.su\\\/?p=87650\\\/#organizationLogo\",\"width\":288,\"height\":90},\"image\":{\"@id\":\"https:\\\/\\\/newsroom.su\\\/?p=87650\\\/#organizationLogo\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/newsroom.su\\\/?author=10#author\",\"url\":\"https:\\\/\\\/newsroom.su\\\/?author=10\",\"name\":\"\\u042f\\u043a\\u043e\\u0432 \\u0411\\u043e\\u0439\\u043a\\u043e\\u0432\",\"image\":{\"@type\":\"ImageObject\",\"@id\":\"https:\\\/\\\/newsroom.su\\\/?p=87650#authorImage\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/9449fdee7bad3db7c477663a848f44bf9df7c8f75b8b11b7140ff198b5f895d1?s=96&d=mm&r=g\",\"width\":96,\"height\":96,\"caption\":\"\\u042f\\u043a\\u043e\\u0432 \\u0411\\u043e\\u0439\\u043a\\u043e\\u0432\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/newsroom.su\\\/?p=87650#webpage\",\"url\":\"https:\\\/\\\/newsroom.su\\\/?p=87650\",\"name\":\"PharmaMar Reaches an Agreement With Impilo Pharma, a Part of Immedica Group, for the Promotion and Distribution of Yondelis(R) in the Nordic Countries and Eastern Europe - newsroom.su\",\"description\":\"MADRID, July 27, 2018\\\/PRNewswire-FirstCall\\\/ -- - PharmaMar will receive an up-front payment of 2 million euros - This agreement will replace the current agreement between PharmaMar and Swedish Orphan Biovitrum International PharmaMar (MCE: PHM) has announced today the signing of an agreement with Impilo Pharma, a part of Immedica Group, for the exclusive promotion and distribution of its antitumour compound, Yondelis(R), throughout the Nordic countries\",\"inLanguage\":\"ru-RU\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/newsroom.su\\\/#website\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/newsroom.su\\\/?p=87650#breadcrumblist\"},\"author\":{\"@id\":\"https:\\\/\\\/newsroom.su\\\/?author=10#author\"},\"creator\":{\"@id\":\"https:\\\/\\\/newsroom.su\\\/?author=10#author\"},\"image\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/newsroom.su\\\/wp-content\\\/uploads\\\/2018\\\/07\\\/11.jpg\",\"@id\":\"https:\\\/\\\/newsroom.su\\\/?p=87650\\\/#mainImage\",\"width\":900,\"height\":590},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/newsroom.su\\\/?p=87650#mainImage\"},\"datePublished\":\"2018-07-30T19:26:05+03:00\",\"dateModified\":\"2018-07-30T19:26:05+03:00\"},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/newsroom.su\\\/#website\",\"url\":\"https:\\\/\\\/newsroom.su\\\/\",\"name\":\"newsroom.su\",\"description\":\"\\u041d\\u043e\\u0432\\u043e\\u0441\\u0442\\u0438 \\u043e \\u043d\\u043e\\u0432\\u043e\\u0441\\u0442\\u044f\\u0445\",\"inLanguage\":\"ru-RU\",\"publisher\":{\"@id\":\"https:\\\/\\\/newsroom.su\\\/#organization\"}}]}\n\t\t<\/script>\n\t\t<!-- All in One SEO -->\n\n","aioseo_head_json":{"title":"PharmaMar Reaches an Agreement With Impilo Pharma, a Part of Immedica Group, for the Promotion and Distribution of Yondelis(R) in the Nordic Countries and Eastern Europe - newsroom.su","description":"MADRID, July 27, 2018\/PRNewswire-FirstCall\/ -- - PharmaMar will receive an up-front payment of 2 million euros - This agreement will replace the current agreement between PharmaMar and Swedish Orphan Biovitrum International PharmaMar (MCE: PHM) has announced today the signing of an agreement with Impilo Pharma, a part of Immedica Group, for the exclusive promotion and distribution of its antitumour compound, Yondelis(R), throughout the Nordic countries","canonical_url":"https:\/\/newsroom.su\/?p=87650","robots":"max-image-preview:large","keywords":"","webmasterTools":{"miscellaneous":""},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"BlogPosting","@id":"https:\/\/newsroom.su\/?p=87650#blogposting","name":"PharmaMar Reaches an Agreement With Impilo Pharma, a Part of Immedica Group, for the Promotion and Distribution of Yondelis(R) in the Nordic Countries and Eastern Europe - newsroom.su","headline":"PharmaMar Reaches an Agreement With Impilo Pharma, a Part of Immedica Group, for the Promotion and Distribution of Yondelis(R) in the Nordic Countries and Eastern Europe","author":{"@id":"https:\/\/newsroom.su\/?author=10#author"},"publisher":{"@id":"https:\/\/newsroom.su\/#organization"},"image":{"@type":"ImageObject","url":"https:\/\/newsroom.su\/wp-content\/uploads\/2018\/07\/11.jpg","width":900,"height":590},"datePublished":"2018-07-30T19:26:05+03:00","dateModified":"2018-07-30T19:26:05+03:00","inLanguage":"ru-RU","mainEntityOfPage":{"@id":"https:\/\/newsroom.su\/?p=87650#webpage"},"isPartOf":{"@id":"https:\/\/newsroom.su\/?p=87650#webpage"},"articleSection":"\u041d\u0430 \u044d\u043a\u0440\u0430\u043d\u0435, \u043c\u0435\u0434\u0438\u0446\u0438\u043d\u0430"},{"@type":"BreadcrumbList","@id":"https:\/\/newsroom.su\/?p=87650#breadcrumblist","itemListElement":[{"@type":"ListItem","@id":"https:\/\/newsroom.su#listItem","position":1,"name":"Home","item":"https:\/\/newsroom.su","nextItem":{"@type":"ListItem","@id":"https:\/\/newsroom.su\/?cat=3#listItem","name":"\u041d\u0430 \u044d\u043a\u0440\u0430\u043d\u0435"}},{"@type":"ListItem","@id":"https:\/\/newsroom.su\/?cat=3#listItem","position":2,"name":"\u041d\u0430 \u044d\u043a\u0440\u0430\u043d\u0435","item":"https:\/\/newsroom.su\/?cat=3","nextItem":{"@type":"ListItem","@id":"https:\/\/newsroom.su\/?p=87650#listItem","name":"PharmaMar Reaches an Agreement With Impilo Pharma, a Part of Immedica Group, for the Promotion and Distribution of Yondelis(R) in the Nordic Countries and Eastern Europe"},"previousItem":{"@type":"ListItem","@id":"https:\/\/newsroom.su#listItem","name":"Home"}},{"@type":"ListItem","@id":"https:\/\/newsroom.su\/?p=87650#listItem","position":3,"name":"PharmaMar Reaches an Agreement With Impilo Pharma, a Part of Immedica Group, for the Promotion and Distribution of Yondelis(R) in the Nordic Countries and Eastern Europe","previousItem":{"@type":"ListItem","@id":"https:\/\/newsroom.su\/?cat=3#listItem","name":"\u041d\u0430 \u044d\u043a\u0440\u0430\u043d\u0435"}}]},{"@type":"Organization","@id":"https:\/\/newsroom.su\/#organization","name":"newsroom.su","description":"\u041d\u043e\u0432\u043e\u0441\u0442\u0438 \u043e \u043d\u043e\u0432\u043e\u0441\u0442\u044f\u0445","url":"https:\/\/newsroom.su\/","logo":{"@type":"ImageObject","url":"https:\/\/newsroom.su\/wp-content\/uploads\/2017\/03\/logo4-2.png","@id":"https:\/\/newsroom.su\/?p=87650\/#organizationLogo","width":288,"height":90},"image":{"@id":"https:\/\/newsroom.su\/?p=87650\/#organizationLogo"}},{"@type":"Person","@id":"https:\/\/newsroom.su\/?author=10#author","url":"https:\/\/newsroom.su\/?author=10","name":"\u042f\u043a\u043e\u0432 \u0411\u043e\u0439\u043a\u043e\u0432","image":{"@type":"ImageObject","@id":"https:\/\/newsroom.su\/?p=87650#authorImage","url":"https:\/\/secure.gravatar.com\/avatar\/9449fdee7bad3db7c477663a848f44bf9df7c8f75b8b11b7140ff198b5f895d1?s=96&d=mm&r=g","width":96,"height":96,"caption":"\u042f\u043a\u043e\u0432 \u0411\u043e\u0439\u043a\u043e\u0432"}},{"@type":"WebPage","@id":"https:\/\/newsroom.su\/?p=87650#webpage","url":"https:\/\/newsroom.su\/?p=87650","name":"PharmaMar Reaches an Agreement With Impilo Pharma, a Part of Immedica Group, for the Promotion and Distribution of Yondelis(R) in the Nordic Countries and Eastern Europe - newsroom.su","description":"MADRID, July 27, 2018\/PRNewswire-FirstCall\/ -- - PharmaMar will receive an up-front payment of 2 million euros - This agreement will replace the current agreement between PharmaMar and Swedish Orphan Biovitrum International PharmaMar (MCE: PHM) has announced today the signing of an agreement with Impilo Pharma, a part of Immedica Group, for the exclusive promotion and distribution of its antitumour compound, Yondelis(R), throughout the Nordic countries","inLanguage":"ru-RU","isPartOf":{"@id":"https:\/\/newsroom.su\/#website"},"breadcrumb":{"@id":"https:\/\/newsroom.su\/?p=87650#breadcrumblist"},"author":{"@id":"https:\/\/newsroom.su\/?author=10#author"},"creator":{"@id":"https:\/\/newsroom.su\/?author=10#author"},"image":{"@type":"ImageObject","url":"https:\/\/newsroom.su\/wp-content\/uploads\/2018\/07\/11.jpg","@id":"https:\/\/newsroom.su\/?p=87650\/#mainImage","width":900,"height":590},"primaryImageOfPage":{"@id":"https:\/\/newsroom.su\/?p=87650#mainImage"},"datePublished":"2018-07-30T19:26:05+03:00","dateModified":"2018-07-30T19:26:05+03:00"},{"@type":"WebSite","@id":"https:\/\/newsroom.su\/#website","url":"https:\/\/newsroom.su\/","name":"newsroom.su","description":"\u041d\u043e\u0432\u043e\u0441\u0442\u0438 \u043e \u043d\u043e\u0432\u043e\u0441\u0442\u044f\u0445","inLanguage":"ru-RU","publisher":{"@id":"https:\/\/newsroom.su\/#organization"}}]},"og:locale":"ru_RU","og:site_name":"newsroom.su - \u041d\u043e\u0432\u043e\u0441\u0442\u0438 \u043e \u043d\u043e\u0432\u043e\u0441\u0442\u044f\u0445","og:type":"article","og:title":"PharmaMar Reaches an Agreement With Impilo Pharma, a Part of Immedica Group, for the Promotion and Distribution of Yondelis(R) in the Nordic Countries and Eastern Europe - newsroom.su","og:description":"MADRID, July 27, 2018\/PRNewswire-FirstCall\/ -- - PharmaMar will receive an up-front payment of 2 million euros - This agreement will replace the current agreement between PharmaMar and Swedish Orphan Biovitrum International PharmaMar (MCE: PHM) has announced today the signing of an agreement with Impilo Pharma, a part of Immedica Group, for the exclusive promotion and distribution of its antitumour compound, Yondelis(R), throughout the Nordic countries","og:url":"https:\/\/newsroom.su\/?p=87650","og:image":"https:\/\/newsroom.su\/wp-content\/uploads\/2017\/03\/logo4-2.png","og:image:secure_url":"https:\/\/newsroom.su\/wp-content\/uploads\/2017\/03\/logo4-2.png","og:image:width":288,"og:image:height":90,"article:published_time":"2018-07-30T16:26:05+00:00","article:modified_time":"2018-07-30T16:26:05+00:00","twitter:card":"summary","twitter:title":"PharmaMar Reaches an Agreement With Impilo Pharma, a Part of Immedica Group, for the Promotion and Distribution of Yondelis(R) in the Nordic Countries and Eastern Europe - newsroom.su","twitter:description":"MADRID, July 27, 2018\/PRNewswire-FirstCall\/ -- - PharmaMar will receive an up-front payment of 2 million euros - This agreement will replace the current agreement between PharmaMar and Swedish Orphan Biovitrum International PharmaMar (MCE: PHM) has announced today the signing of an agreement with Impilo Pharma, a part of Immedica Group, for the exclusive promotion and distribution of its antitumour compound, Yondelis(R), throughout the Nordic countries","twitter:image":"https:\/\/newsroom.su\/wp-content\/uploads\/2017\/03\/logo4-2.png"},"aioseo_meta_data":{"post_id":"87650","title":null,"description":null,"keywords":null,"keyphrases":null,"primary_term":null,"canonical_url":null,"og_title":null,"og_description":null,"og_object_type":"default","og_image_type":"default","og_image_url":null,"og_image_width":null,"og_image_height":null,"og_image_custom_url":null,"og_image_custom_fields":null,"og_video":null,"og_custom_url":null,"og_article_section":null,"og_article_tags":null,"twitter_use_og":false,"twitter_card":"default","twitter_image_type":"default","twitter_image_url":null,"twitter_image_custom_url":null,"twitter_image_custom_fields":null,"twitter_title":null,"twitter_description":null,"schema":{"blockGraphs":[],"customGraphs":[],"default":{"data":{"Article":[],"Course":[],"Dataset":[],"FAQPage":[],"Movie":[],"Person":[],"Product":[],"ProductReview":[],"Car":[],"Recipe":[],"Service":[],"SoftwareApplication":[],"WebPage":[]},"graphName":"BlogPosting","isEnabled":true},"graphs":[]},"schema_type":"default","schema_type_options":null,"pillar_content":false,"robots_default":true,"robots_noindex":false,"robots_noarchive":false,"robots_nosnippet":false,"robots_nofollow":false,"robots_noimageindex":false,"robots_noodp":false,"robots_notranslate":false,"robots_max_snippet":null,"robots_max_videopreview":null,"robots_max_imagepreview":"large","priority":null,"frequency":null,"local_seo":null,"breadcrumb_settings":null,"limit_modified_date":false,"ai":null,"created":"2022-06-26 14:26:21","updated":"2025-08-25 00:21:17","seo_analyzer_scan_date":null},"aioseo_breadcrumb":"<div class=\"aioseo-breadcrumbs\"><span class=\"aioseo-breadcrumb\">\n\t\t\t<a href=\"https:\/\/newsroom.su\" title=\"Home\">Home<\/a>\n\t\t<\/span><span class=\"aioseo-breadcrumb-separator\">&raquo;<\/span><span class=\"aioseo-breadcrumb\">\n\t\t\t<a href=\"https:\/\/newsroom.su\/?cat=3\" title=\"\u041d\u0430 \u044d\u043a\u0440\u0430\u043d\u0435\">\u041d\u0430 \u044d\u043a\u0440\u0430\u043d\u0435<\/a>\n\t\t<\/span><span class=\"aioseo-breadcrumb-separator\">&raquo;<\/span><span class=\"aioseo-breadcrumb\">\n\t\t\tPharmaMar Reaches an Agreement With Impilo Pharma, a Part of Immedica Group, for the Promotion and Distribution of Yondelis(R) in the Nordic Countries and Eastern Europe\n\t\t<\/span><\/div>","aioseo_breadcrumb_json":[{"label":"Home","link":"https:\/\/newsroom.su"},{"label":"\u041d\u0430 \u044d\u043a\u0440\u0430\u043d\u0435","link":"https:\/\/newsroom.su\/?cat=3"},{"label":"PharmaMar Reaches an Agreement With Impilo Pharma, a Part of Immedica Group, for the Promotion and Distribution of Yondelis(R) in the Nordic Countries and Eastern Europe","link":"https:\/\/newsroom.su\/?p=87650"}],"_links":{"self":[{"href":"https:\/\/newsroom.su\/index.php?rest_route=\/wp\/v2\/posts\/87650","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/newsroom.su\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/newsroom.su\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/newsroom.su\/index.php?rest_route=\/wp\/v2\/users\/10"}],"replies":[{"embeddable":true,"href":"https:\/\/newsroom.su\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=87650"}],"version-history":[{"count":0,"href":"https:\/\/newsroom.su\/index.php?rest_route=\/wp\/v2\/posts\/87650\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/newsroom.su\/index.php?rest_route=\/wp\/v2\/media\/87652"}],"wp:attachment":[{"href":"https:\/\/newsroom.su\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=87650"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/newsroom.su\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=87650"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/newsroom.su\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=87650"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}